DaVita Inc. reported consolidated revenues of USD 3.62 billion for the fourth quarter (Q4) of 2025 and USD 13.64 billion for the full year (FY) 2025. Net income from continuing operations stood at USD 209 million for Q4 2025 and USD 722 million for FY 2025. Diluted earnings per share $(EPS)$ from continuing operations were USD 2.94 for Q4 and USD 9.51 for the year. Adjusted net income from continuing operations was USD 242 million for Q4 2025 and USD 818 million for FY 2025, with adjusted diluted EPS of USD 3.40 and USD 10.78, respectively. Total net income amounted to USD 234 million for Q4 2025 and USD 747 million for FY 2025. Diluted EPS was USD 3.29 for Q4 and USD 9.84 for the year. DaVita’s effective income tax rate on income from continuing operations was 20.0 percent for Q4 2025 and 21.8 percent for FY 2025. The company reported operating income of USD 561 million and adjusted operating income of USD 586 million for Q4 2025. Chief Executive Officer Javier Rodriguez stated that DaVita’s performance in 2025 met its financial targets despite a challenging environment, citing ongoing investments and process improvements as drivers for continued clinical and financial delivery into 2026 and beyond.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DaVita Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000927066-26-000004), on February 02, 2026, and is solely responsible for the information contained therein.
Comments